Lyell Immunopharma (NASDAQ:LYEL) Trading Up 8.5%

Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Rating)’s share price was up 8.5% during trading on Monday . The company traded as high as $2.24 and last traded at $2.16. Approximately 125,607 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 970,433 shares. The stock had previously closed at $1.99.

Analyst Ratings Changes

A number of equities research analysts have commented on LYEL shares. HC Wainwright reduced their price objective on Lyell Immunopharma from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, March 2nd. Morgan Stanley reduced their price objective on Lyell Immunopharma from $7.00 to $4.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 24th.

Lyell Immunopharma Price Performance

The stock has a fifty day moving average price of $2.80 and a two-hundred day moving average price of $4.56. The company has a market cap of $586.58 million, a P/E ratio of -3.18 and a beta of -1.68.

Lyell Immunopharma (NASDAQ:LYEL – Get Rating) last posted its earnings results on Tuesday, February 28th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.28. Lyell Immunopharma had a negative return on equity of 21.53% and a negative net margin of 216.24%. The company had revenue of $48.39 million for the quarter, compared to analyst estimates of $2.85 million. Equities analysts predict that Lyell Immunopharma, Inc. will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Hedge funds have recently bought and sold shares of the business. E Fund Management Co. Ltd. bought a new stake in Lyell Immunopharma during the third quarter worth $104,000. Massachusetts Financial Services Co. MA lifted its holdings in Lyell Immunopharma by 7.3% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,059,897 shares of the company’s stock worth $7,769,000 after acquiring an additional 71,788 shares during the period. New York State Common Retirement Fund lifted its holdings in Lyell Immunopharma by 7.3% during the third quarter. New York State Common Retirement Fund now owns 117,792 shares of the company’s stock worth $863,000 after acquiring an additional 8,050 shares during the period. Barclays PLC lifted its holdings in Lyell Immunopharma by 1,451.2% during the third quarter. Barclays PLC now owns 134,708 shares of the company’s stock worth $988,000 after acquiring an additional 126,024 shares during the period. Finally, Camden Capital LLC bought a new stake in Lyell Immunopharma during the third quarter worth $110,000. 45.04% of the stock is currently owned by institutional investors.

Lyell Immunopharma Company Profile

(Get Rating)

Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.